STRAP.CO Strategic Partners A/S

Healthcare Biotechnology Copenhagen Exchange
635.00 DKK
Close of Oct 29, 2026
Market cap
DKK 34.4M
P/E
20.0x
P/B
1.81x
ROE
21.0%
Dividend yield
-
Fundamental score
1.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is STRAP.CO undervalued?

Graham number
Price635.00
Graham value500.11
Premium27.0%

STRAP.CO trades 27.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Strategic Partners A/S fundamental analysis

6 of 22 checks passed

ROE 2/2

High return on equity (21.0%), above 20%.

ROA 1/1

Return on assets (20.3%) is above the industry median (18.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-156.6%) is below the industry median (24.3%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 0/1

No interest expense reported.

PE vs Market 0/1

PE (20.0x) is above the market median (17.0x).

PE vs Industry 0/1

PE (20.0x) is above the industry median (16.4x).

PBV 1/1

Price to book (1.8x) is below the industry median (5.1x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 36.3, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Strategic Partners A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Strategic Partners A/S

Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. Strategic Partners A/S was incorporated in 2009 and is based in Herlev, Denmark.

Full company profile